Literature DB >> 9649638

Risk factors for recurrence of hepatitis C after liver transplantation.

J I Herrero1, A de la Peña, J Quiroga, B Sangro, N García, I Sola, J A Cienfuegos, M P Civeira, J Prieto.   

Abstract

Recurrent hepatitis C is a frequent complication after liver transplantation for hepatitis C virus-related cirrhosis, but risk factors related to its development remain ill defined. Twenty-three patients receiving a primary liver graft for hepatitis C virus-related cirrhosis and with an assessable biopsy performed at least 6 months after liver transplantation were studied retrospectively. The end point of this study was to look for risk factors associated with the development of histologic hepatitis C in the graft. Thirty-six major variables were studied, and those reaching significance by univariate analysis were included in a multivariate analysis. Eighteen patients (78%) developed posttransplant hepatitis C. On univariate analysis, six variables showed significant predictive value: increased immunosuppression for treatment of acute rejection; pretransplant hepatocellular carcinoma; cumulative doses of prednisone at 3, 6, and 12 months after transplantation; and mean blood trough levels of cyclosporine in the first 6 months posttransplantation. On multivariate analysis, two variables retained independent statistical significance as predictors of hepatitis C recurrence, namely receipt of antirejection therapy (P = .0087) and lower mean cyclosporine levels in the first 6 months after transplantation (P = .0134). Therefore, recurrence of hepatitis C after liver transplantation seems to be at least partially related to posttransplantation immunosuppressive therapy. Copyright 1998 W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649638     DOI: 10.1002/lt.500040406

Source DB:  PubMed          Journal:  Liver Transpl Surg        ISSN: 1074-3022


  4 in total

1.  Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience.

Authors:  R M Ghobrial; D G Farmer; A Baquerizo; S Colquhoun; H R Rosen; H Yersiz; J F Markmann; K E Drazan; C Holt; D Imagawa; L I Goldstein; P Martin; R W Busuttil
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

2.  A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients.

Authors:  R M Ghobrial; R Steadman; J Gornbein; C Lassman; C D Holt; P Chen; D G Farmer; H Yersiz; N Danino; E Collisson; A Baquarizo; S S Han; S Saab; L I Goldstein; J A Donovan; K Esrason; R W Busuttil
Journal:  Ann Surg       Date:  2001-09       Impact factor: 12.969

Review 3.  Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents.

Authors:  Jinhe Han; Myoung Kyu Lee; Yejin Jang; Won-Jea Cho; Meeheyin Kim
Journal:  Drug Discov Today       Date:  2022-05-21       Impact factor: 8.369

4.  Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C.

Authors:  M Wali; R F Harrison; P J Gow; D Mutimer
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.